Patents by Inventor Tal Zaks
Tal Zaks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12150980Abstract: The invention relates to concatemeric peptide epitope RNAs, as well as methods and compositions thereof. mRNA vaccines are also provided according to the invention, including cancer vaccines.Type: GrantFiled: July 29, 2016Date of Patent: November 26, 2024Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Nicholas Valiante, Tal Zaks
-
Publication number: 20240366745Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.Type: ApplicationFiled: April 15, 2024Publication date: November 7, 2024Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks
-
Patent number: 12042527Abstract: The disclosure features methods for treating solid tumor malignancies and lymphomas by administering LNP encapsulated mRNAs encoding human OX40L, IL-23 and IL-36? polypeptides alone or in combination with checkpoint blockade. The disclosure also features compositions for use in the methods.Type: GrantFiled: January 8, 2020Date of Patent: July 23, 2024Assignee: ModernaTX, Inc.Inventors: Robert Meehan, Tal Zaks
-
Publication number: 20230020362Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.Type: ApplicationFiled: May 5, 2022Publication date: January 19, 2023Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
-
Publication number: 20220378904Abstract: Provided herein are vaccine composition comprising a chemically-modified messenger ribonucleic acid (mRNA) encoding a hMPV fusion (F) glycoprotein and a chemically-modified mRNA encoding a hPIV3 F glycoprotein formulated in a cationic lipid nanoparticle formulation, and related method for inducing an antigen-specific immune response.Type: ApplicationFiled: May 5, 2022Publication date: December 1, 2022Applicant: ModernaTX, Inc.Inventors: Lori Panther, Christine Shaw, Igor Smolenov, Michael Watson, Tal Zaks
-
Publication number: 20220370354Abstract: This disclosure relates to mRNA therapy for the treatment of methylmalonic acidemia (MMA). mRNAs for use in the invention, when administered in vivo, encode methylmalonyl-CoA mutase (MUT). mRNA therapies of the disclosure increase and/or restore deficient levels of MUT expression and/or activity in subjects.Type: ApplicationFiled: May 8, 2020Publication date: November 24, 2022Inventors: Tal Zaks, Kelly Lindert, Lin Tung Guey
-
Publication number: 20220347292Abstract: Aspects of the invention relate to methods for producing an antigen-specific immune response to human cytomegalovirus (hCMV) in a subject by administering mRNA vaccines comprising hCMV antigenic polypeptides gH, gL, UL128, UL130, UL131 A and gB formulated in lipid nanoparticles, wherein the antigen-specific immune response to hCMV results in neutralizing antibodies that have i) a geometric mean titer of at least 3-fold against epithelial cell infection or ii) a geometric mean ratio of 9-41 against epithelial cell infection or iii) a geometric mean ratio of 4-8-fold against fibroblast infection.Type: ApplicationFiled: September 11, 2020Publication date: November 3, 2022Applicant: ModernaTX, Inc.Inventors: Lori Panther, Shinu John, Tal Zaks
-
Publication number: 20220257746Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.Type: ApplicationFiled: February 1, 2022Publication date: August 18, 2022Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks
-
Patent number: 11364292Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.Type: GrantFiled: June 10, 2020Date of Patent: June 21, 2022Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
-
Patent number: 11351242Abstract: Provided herein are vaccine composition comprising a chemically-modified messenger ribonucleic acid (mRNA) encoding a hMPV fusion (F) glycoprotein and a chemically-modified mRNA encoding a hPIV3 F glycoprotein formulated in a cationic lipid nanoparticle formulation, and related method for inducing an antigen-specific immune response.Type: GrantFiled: February 11, 2020Date of Patent: June 7, 2022Assignee: ModernaTX, Inc.Inventors: Lori Panther, Christine Shaw, Igor Smolenov, Michael Watson, Tal Zaks
-
Publication number: 20220152178Abstract: The invention relates to concatemeric peptide epitope RNAs, as well as methods and compositions thereof. mRNA vaccines are also provided according to the invention, including cancer vaccines.Type: ApplicationFiled: December 17, 2021Publication date: May 19, 2022Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Nicholas Valiante, Tal Zaks
-
Patent number: 11278611Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.Type: GrantFiled: April 16, 2020Date of Patent: March 22, 2022Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks
-
Patent number: 11235052Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.Type: GrantFiled: April 21, 2020Date of Patent: February 1, 2022Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks, Sayda Mahgoub Elbashir
-
Publication number: 20200368344Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.Type: ApplicationFiled: June 10, 2020Publication date: November 26, 2020Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
-
Publication number: 20200368343Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.Type: ApplicationFiled: June 10, 2020Publication date: November 26, 2020Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu
-
Publication number: 20200289638Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.Type: ApplicationFiled: April 16, 2020Publication date: September 17, 2020Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks
-
Publication number: 20200289639Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.Type: ApplicationFiled: April 21, 2020Publication date: September 17, 2020Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks, Sayda Mahgoub Elbashir
-
Patent number: 10702597Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.Type: GrantFiled: June 15, 2018Date of Patent: July 7, 2020Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
-
Patent number: 10675342Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.Type: GrantFiled: September 20, 2018Date of Patent: June 9, 2020Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks, Sayda Mahgoub Elbashir
-
Patent number: 10517940Abstract: The disclosure relates to Zika virus infection and the treatment thereof. The invention includes ribonucleic acid compositions, as well as methods of using the compositions for treating and preventing Zika virus infection.Type: GrantFiled: September 20, 2018Date of Patent: December 31, 2019Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks